Ultrasound-Guided Radiofrequency Ablation Using a New Electrode with an Electromagnetic Position Sensor for Hepatic Tumors Difficult to Place an Electrode: A Preliminary Clinical Study
- 307 Downloads
To evaluate whether a new electrode embedded with an electromagnetic position sensor (EMPS) improves the technical feasibility of percutaneous radiofrequency ablation (RFA) in patients with hepatic tumors difficult to place an electrode under ultrasonography (US) guidance and to assess short-term therapeutic efficacy and safety.
Materials and Methods
This prospective study was approved by the institutional review board, and written informed consent was obtained from all patients. Between January 2015 and December 2016, 10 patients (7 men and 3 women; age range 52–75 years) with a single hepatic tumor (median 1.4 cm; range 1.1–1.8 cm) difficult to place an electrode under US guidance were enrolled. The technical feasibility of targeting and overlapping ablation during the RFA procedure was graded using a four-point scale and analyzed using the Wilcoxon signed rank test according to the use of EMPS. In addition, the rates of technical success, local tumor progression (LTP), and major complications were assessed.
The use of the new RF electrode with EMPS significantly improved the technical feasibility of targeting and overlapping ablation (p = 0.002 and p = 0.003, respectively). After treatment, the technical success rate was 100%. LTP was not found in any patient during the follow-up period (median 8 months; range 4–22 months). No major procedure-related complications occurred.
The technical feasibility of percutaneous RFA improves with the use of this RF electrode embedded with an EMPS. Short-term therapeutic efficacy and safety after RFA using the electrode were promising in patients with hepatic tumors difficult to place an electrode under US guidance.
KeywordsLiver Ultrasonography Radiofrequency ablation Electromagnetic position sensor Needle tracking
Electromagnetic position sensor
Local tumor progression
Magnetic resonance imaging
The authors thank Mr. Joon Hyok Lee (STARmed, Goyang, South Korea) for his technical assistance.
Financial support and the investigational RF ablation device for this study were provided by STARmed (Goyang, Korea). However, the authors had complete control of the data and information submitted for publication, which was unbiased by the industry.
Compliance with Ethical Standards
Conflict of interest
The authors do not have any conflicts of interest to declare.
Supplementary material 1 (WMV 7289 kb)
- 7.Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195(3):758–65.CrossRefPubMedGoogle Scholar
- 21.Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: local control rate and risk of peritoneal seeding at long-term follow-up. Clin Radiol. 2013;68(12):e641–51.CrossRefPubMedGoogle Scholar